雷贝拉唑治疗慢性萎缩性胃炎的疗效观察

The Curative Effect Observation on Rabeprazole in the Consociation Treatment of Chronic Atrophic Gastritis

目的探讨雷贝拉唑、阿莫西林、克拉霉素、维生素C联合治疗慢性萎缩性胃炎(CAG)的临床疗效。方法将118例CAG患者随机分为两组:雷贝拉唑组60例,口服雷贝拉唑10mgbid;奥美拉唑组58例,口服奥美拉唑20mgbid,其余药物均相同,疗程为7d。结果雷贝拉唑为主的治疗方案在HP的根除率(93.33%)、药物不良反应(6.67%)两方面均优于奥美拉唑组(72.41%和15.51%),两组相比有显著差异(P均<0.05);而胃黏膜病变的逆转和临床症状的改善两组比较,则无明显差异。结论雷贝拉唑联合阿莫西林、克拉霉素、维生素C治疗CAG的方案具有高HP清除率,药物不良反应少等优点,同时又能改善CAG的临床症状,一定程度上逆转胃黏膜病变,是目前治疗CAG较理想的方案之一。

Objective To observe the clinical curative effect of rabeprazole, amxicillin, clarithromycin and vitamin C in the consociation treatment of chronic atrophic gastritis (CAG).Methods The 118 CAG patients were divided into rabeprazole group (60) and omaprazole group (58) at random, which were mainly given rabeprazole (10 mg, bid) and omaprazole (20 mg, bid) respectively for seven days. Results There were significantly statistical differences in the clearance rate of helicobacteria pylori and in the incidence of adverse events between the two groups. The clearance rate of helicobacteria pylori of the rabeprazole group (93.33%) was clearly higher than that of the omaprazolegroup (72.41%), and the incidence of adverse events (6.67%) was clearly lower than that of the omaprazole group (15.51%). There were no statistical differences between the two groups in the relief rate of clinical symptoms and the conversion of stomach mucosa's pathological changes. Conclusion High clearance rate of helicobacteria pylori and low incidence of adverse events were the advantages of rabeprazole therapy, which was one of the good projects in curing CAG.